Results of Treatment With Telmisartan‐Amlodipine in Hypertensive Patients

This randomized 4×4 factorial study determined the efficacy and safety of telmisartan (T) plus amlodipine (A) in hypertensive patients. Adults (N=1461) with stage 1 or 2 hypertension (baseline blood pressure [BP]: 153.2[12.1]/101.7[4.3] mm Hg) were randomized to 1 of 16 treatment groups with T 0, 20, 40, 80 mg and A 0, 2.5, 5, 10 mg for 8 weeks. In‐clinic BP reductions were greater with combination therapy than respective monotherapies. The greatest least‐square mean systolic/diastolic BP reductions were observed with T80 mg plus A10 mg (−26.4/−20.1 mm Hg; P90% with this combination. Peripheral edema was most common in the A10‐mg group (17.8%); however, this rate was notably lower when A was used in combination with T: 11.4% (T20/A10), 6.2% (T40/A10), and 11.3% (T80/A10).